510(k) device
Nexstim Navigated Brain Therapy (NBT) System 2
Nexstim Plc · Transcranial Magnetic Stimulator (OBP, Class II) · First FDA decision Nov 10, 2017, newest Mar 22, 2019DepressionOCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
14
Naming "Navigated Brain Therapy"
MAUDE reports
0
Brand "Navigated Brain Therapy", since 2015
PubMed studies
0
Mentioning "Navigated Brain Therapy"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Nexstim Navigated Brain Therapy (NBT) System 2
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K182700 · Decided Mar 22, 2019 · 176 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K171902 · Decided Nov 10, 2017 · 137 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcranial Magnetic StimulationLocal determinationIn effectL33398Wellpoint FederalUpdated Jul 16, 2026
- Transcranial Magnetic StimulationProposed local determinationProposedDL33398National Government Services, Inc.Updated Mar 27, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL34641WPS Insurance CorporationUpdated Mar 20, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL37086Noridian Healthcare Solutions, LLCUpdated Aug 6, 2025
- Repetitive Transcranial Magnetic Stimulation (rTMS) in AdultsLocal determinationIn effectL34869Palmetto GBAUpdated Jan 7, 2025
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL36469CGS Administrators, LLCUpdated May 30, 2024
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "Navigated Brain Therapy", any status and sponsor, newest update first.
- Image-guided, Robot Navigated Transcranial Magnetic Stimulation (IR-TMS) for Alcohol Use Disorder (AUD)Pivotal-lookingRecruiting
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT06648642 · 150 participants (planned) · Start Feb 3, 2025 · Primary completion May 31, 2027
Device: Transcranial Magnetic Stimulation (TMS) · For: Alcohol Use Disorder
Sites: San Antonio, Texas
- Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) DeficiencyRecruiting
Boston Children's HospitalAcademic, hospital or other
NCT03758521 · 55 participants (planned) · Start Jan 15, 2019 · Primary completion May 31, 2029
Device: Transcranial magnetic stimulation (TMS); Magnetic resonance imaging (MRI) and 1 more · For: Succinic Semialdehyde Dehydrogenase Deficiency
Sites: Boston, Massachusetts; Heidelberg, Germany; Barcelona, Spain · 4 sites in all
- Physiology of Human Brain ConnectivityRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06246942 · 80 participants (planned) · Start Dec 13, 2024 · Primary completion Apr 15, 2027
Device: Single-pulse transcranial magnetic stimulation (spTMS); Paired associative stimulation (PAS) · For: Healthy
Sites: Boston, Massachusetts
11 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Navigated Brain Therapy", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OBP
337 reports: 9 malfunction, 323 injury, 2 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Navigated Brain Therapy"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OBP.
- NeuroStar TMS Therapy SystemNeuronetics, Inc. · 510(k) 2022
- BrainsWay Deep TMS SystemBrainsway , Ltd. · 510(k) 2025
- Apollo TMS Therapy SystemMag & More GmbH · 510(k) 2026
- MagVita TMS Therapy w/MagPro R20Tonica Elektronik A/S · 510(k) 2017
- NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 510(k) 2024
- Magstim Horizon 3.0 TMS Therapy SystemMagstim Company, Ltd. · 510(k) 2023
- HORIZON TMS Therapy System with NavigationMagstim Company, Ltd. · 510(k) 2019
- Nexstim Navigated Brain Stimulation (NBS) 6 System (NBS6)Nexstim Oyj · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.